Physician profile
Floyd E Trinidad
NPI 1780730168
$677.35
in general payments reported to CMS, 2019-2025
18 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.63 · 2022: $94.55 · 2023: $59.18 · 2024: $269 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $114.31 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $112.72 | 2022-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $65.20 | 2022-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $62.80 | 2024-2025 | |
| Abbott Laboratories | $54.36 | 2023-2025 | Proclaim |
| Pfizer INC. | $39.13 | 2024-2025 | |
| Konica Minolta Healthcare Americas, INC | $25.73 | 2019 | |
| Edwards Lifesciences Corporation | $25.39 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Spinal Simplicity, LLC | $21.87 | 2025 | Ha Minuteman G3-R |
| Astellas Pharma US INC | $19.92 | 2024 | Veozah |
| Nalu Medical, INC. | $19.57 | 2023 | Nalu Neurostimulation System |
| Otsuka America Pharmaceutical, INC. | $19.32 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $19.02 | 2022 | |
| Vanda Pharmaceuticals INC. | $17.77 | 2025 | Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $16.17 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $15.49 | 2022 | |
| Tearlab Corp | $14.90 | 2019 | |
| Exact Sciences Corporation | $13.68 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floyd Trinidad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.